BODK

Established in 2021 and based in Dongguan, China, BODK operates as a medical technology company that focuses on life science robot product technology R&D. The company has acquired more than 100 patents and software copyrights. The core research team members graduated from the University of Tokyo in Japan, Washington University in the United States, Peking University, Jiangnan University, and Nanjing Medical University. Zhaoqiang Liu, the founder, once served as general manager of the South China Business Department of Future Partner Robot Company.

Kun Lu, the CTO, is a postdoctoral fellow at NDPE National Research Center for Drug Policy and Pharmaceutical Industry Economics. In 2023, BODK set up a lab in Guangzhou. In September 2024, it closed a series A funding led by Dingsheng Hechuang Investment Management (Beijing). BODK provides life science scene automation solutions, including cell culture automation solutions, medical testing intelligent solutions, experimental animal management solutions, supporting consumables and reagents, and ultra-clean engineering design and construction.

It combines artificial intelligence with life sciences to develop centrifugal washing robots, liquid waste robots and incubator robots. Products can be applied in AI intelligent medical equipment and smart medical scenarios, such as fully automatic cell culture systems, artificial intelligence medical testing laboratories and separate collaborative robots. The company has many clients, such as Zhongxu Medical, Zhongzhen Biology and Zhongmei Ser. The company generates revenue by developing and launching modular robot products including centrifuge robots, incubator robots, and liquid adding robots.

The company will use the series A funding for R&D investment, talent recruitment and market industry chain construction.